Amlodipine
- Generic Name
- Amlodipine
- Brand Names
- Amlobenz, Azor, Caduet, Dafiro, Exforge, Exforge Hct, Katerzia, Lotrel, Norliqva, Norvasc, Prestalia, Tribenzor, Twynsta, Viacoram
- Drug Type
- Small Molecule
- Chemical Formula
- C20H25ClN2O5
- CAS Number
- 88150-42-9
- Unique Ingredient Identifier
- 1J444QC288
- Background
Amlodipine, initially approved by the FDA in 1987, is a popular antihypertensive drug belonging to the group of drugs called dihydropyridine calcium channel blockers. Due to their selectivity for the peripheral blood vessels, dihydropyridine calcium channel blockers are associated with a lower incidence of myocardial depression and cardiac conduction abnormalities than other calcium channel blockers .
Amlodipine is commonly used in the treatment of high blood pressure and angina. Amlodipine has antioxidant properties and an ability to enhance the production of nitric oxide (NO), an important vasodilator that decreases blood pressure . The option for single daily dosing of amlodipine is an attractive feature of this drug .
- Indication
Amlodipine may be used alone or in combination with other antihypertensive and antianginal agents for the treatment of the following conditions :
• Hypertension
• Coronary artery disease
• Chronic stable angina
• Vasospastic angina (Prinzmetal’s or Variant angina)
• Angiographically documented coronary artery disease in patients without heart failure or an ejection fraction < 40%
- Associated Conditions
- Cardiovascular Events, Chronic Stable Angina Pectoris, Coronary Artery Disease (CAD), Homozygous Familial Hypercholesterolaemia (HoFH), Hypertension, Hypertension, Essential Hypertension, Mixed Dyslipidemias, Primary Hypercholesterolemia, Vasospastic Angina
Calcium Channel Blocker Amlodipine for Endometrial Cancer Therapy
- Conditions
- Endometrial CancerAtypical Endometrial Hyperplasia
- Interventions
- First Posted Date
- 2025-04-24
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 140
- Registration Number
- NCT06942377
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
Personalised Electronic Record Supported Optimisation of Amlodipine for Patients With Hypertension
- First Posted Date
- 2024-12-03
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Queen Mary University of London
- Registration Number
- NCT06713785
Statin Combined with Amlodipine Treats Primary Aldosteronism
- Conditions
- Primary AldosteronismStatinMineralocorticoid Receptor AntagonistHypertension
- Interventions
- First Posted Date
- 2024-07-26
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Third Military Medical University
- Target Recruit Count
- 180
- Registration Number
- NCT06523465
- Locations
- 🇨🇳
No. 10 Changjiang River Branch, Yuzhong District，Chongqing, China, Chongqing, Chongqing, China
To Assess Allisartan Isoproxil/Amlodipine in Patients With Essential Hypertension Uncontrolled With Amlodipine or Allisartan Isoproxil
- Conditions
- Essential Hypertension
- Interventions
- Drug: Allisartan Isoproxil/Amlodipine group 1Drug: Allisartan Isoproxil/Amlodipine group 2Drug: Allisartan Isoproxil group 2
- First Posted Date
- 2024-06-18
- Last Posted Date
- 2024-06-28
- Lead Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 499
- Registration Number
- NCT06465264
- Locations
- 🇨🇳
Beijing Chaoyang Hospital, Capital Medical University, Beijing, Beijing, China
Efficacy of Targeted Medical Therapy in Angina and Nonobstructive Coronary Arteries
- Conditions
- Angina PectorisMyocardial Bridge of Coronary ArteryMicrovascular AnginaVasospastic Angina
- Interventions
- First Posted Date
- 2024-05-22
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 150
- Registration Number
- NCT06424834
- Locations
- 🇺🇸
Stanford Hospital, Palo Alto, California, United States
Effects of Valsartan vs Amlodipine and Low BP on Kidney Outcomes in Essential Hypertension
- Conditions
- Essential Hypertension
- Interventions
- First Posted Date
- 2024-05-02
- Last Posted Date
- 2024-05-02
- Lead Sponsor
- Oslo University Hospital
- Target Recruit Count
- 15313
- Registration Number
- NCT06395194
Evaluation of the Antihypertensive effectIveness, Tolerability, and Adherence With Amlodipine/ Indapamide/ Perindopril Triple Single-pill Combination in Hypertensive Patients Without Concomitant Antihypertensive Therapy (TRIPTYCH)
- Conditions
- Arterial HypertensionHTN
- First Posted Date
- 2024-02-14
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- Servier Russia
- Target Recruit Count
- 375
- Registration Number
- NCT06259175
Bioequivalence Study of Amlodipine/Valsartan 10/160 mg Film Coated Tablets
- Conditions
- Healthy Volunteer
- Interventions
- Drug: Amlodipine/Valsartan
- First Posted Date
- 2024-01-05
- Last Posted Date
- 2024-01-09
- Lead Sponsor
- International Bio service
- Target Recruit Count
- 48
- Registration Number
- NCT06193044
A Study of Angiotensin-II Receptor Blocker on Cardiovascular Remodeling (VALUE Trial)
- Conditions
- Coarctation of AortaHigh Blood Pressure
- Interventions
- First Posted Date
- 2023-11-29
- Last Posted Date
- 2024-07-29
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 120
- Registration Number
- NCT06150560
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
Skin Sodium and Salt Sensitivity of Blood Pressure
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2023-08-04
- Last Posted Date
- 2023-08-04
- Target Recruit Count
- 60
- Registration Number
- NCT05976438
- Locations
- 🇬🇧
Addenbrooke's Hospital, Cambridge, United Kingdom
🇬🇧St Thomas' Hospital, London, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.